Transmedics Group Inc (NASDAQ:TMDX) shares, rose in value, with the stock price up by 2.46% to the previous day’s close as strong demand from buyers drove the stock to $77.20.
Actively observing the price movement in the last trading, the stock closed the session at $75.35. The value of beta (5-year monthly) was 2.00. Referring to stock’s 52-week performance, its high was $99.63, and the low was $36.42. On the whole, TMDX has fluctuated by -6.31% over the past month.
With the market capitalization of Transmedics Group Inc currently standing at about $2.53 billion, investors are eagerly awaiting this quarter’s results, scheduled for Apr 29, 2024 – May 03, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.05, which is expected to increase to $0.28 for fiscal year -$0.23 and then to about $0.32 by fiscal year 2025. Data indicates that the EPS growth is expected to be 70.10% in 2025, while the next year’s EPS growth is forecast to be 239.10%.
Analysts have estimated the company’s revenue for the quarter at $83.78 million, with a low estimate of $81.2 million and a high estimate of $85.5 million. According to the average forecast, sales growth in current quarter could jump up 101.60%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $366.99 million, representing an increase of 51.90% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that TMDX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of TMDX currently trading nearly 0.21% and -6.47% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.23, while the 7-day volatility ratio is showing 7.46% which for the 30-day chart, stands at 5.34%. Furthermore, Transmedics Group Inc (TMDX)’s beta value is 1.98, and its average true range (ATR) is 4.66.
A comparison of Transmedics Group Inc (TMDX) with its peers suggests the former has fared considerably weaker in the market. TMDX showed an intraday change of 2.46% in last session, and over the past year, it grew by 2.69%%.
Data on historical trading for Transmedics Group Inc (NASDAQ:TMDX) indicates that the trading volumes over the past 10 days have averaged 0.73 million and over the past 3 months, they’ve averaged 640.30K. According to company’s latest data on outstanding shares, there are 32.67 million shares outstanding.
Nearly 3.79% of Transmedics Group Inc’s shares belong to company insiders and institutional investors own 109.01% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.41 million shares as on Mar 15, 2024, resulting in a short ratio of 6.04. According to the data, the short interest in Transmedics Group Inc (TMDX) stood at 16.53% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 4.93 million. The stock has fallen by -2.19% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TMDX stock heading into the next quarter.
